India Poised to Become Global Hub for Clinical Trials

As an executive of a contract research company, Parexel, noted to Reutert on Wednesday, India is poised to act as a replacement location for early phase clinical trials to reduce the disruptions caused by the Russia Ukraine war. “The US-based company intends to increase its workforce in India to over 8,000 in the next 3 to 5 years from 6,000 currently," Sanjay Vyas, who is in charge of Parexel's India operations, said. “India is already positioned to receive foreign clinical trials that are postponed because of geopolitical issues like the Russia Ukraine war as well as the restrictions placed by multinational pharmaceutical companies on China.” Reports of suspended trials from Ukraine surfaced in the latter years after many large companies and researchers were utilizing Ukraine as a key region for new drug trials prior to Russia's invasion in 2022. Vyas claimed that Parexel intends to recruit to fill positions that will allow the creation of innovation centers. 
Active battle continues to rage after Afghanistan won the toss and chose to field first. Live score updates for AFG vs ENG, Champions Trophy 2025: Archer strikes and Gurbaz is out for 6. "He mentioned during the BioAsia conference I Telangana that, worsen case scenario or worst of instances is far lower in India than it is anywhere else. “

Parexel, a leading clinical research organization based in Durham North Carolina, operates 100 to 150 trial sites throughout India in several states such as Maharashtra, Karnataka, Telangana and Tamil Nadu. 

U.S. based GrandView Research suggests that the clinical trials market data for India will increase to $1.51 billion dollars by 2025. 

Although there is an improvement in India’s image as a reputable and trusted region for conducting clinical trials. India still faces many issues, such as non standard regulations in certain medium level studies, which challenges its inclination as the preferred destination for pharmaceutical companies. 

“If you don’t do phase 1 trials, the same patient will have to wait for a phase 3 (late-stage) trial to happen for the drug to come into the market which in turn causes time to be wasted,” Vyas said. 

He also pointed to another set of problems for India: insufficient knowledge concerning other treatment options by patients and physicians. And starting trial sites in the hinterland are still issues.